Search the Newsreel

Bionano Genomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BNGO)

Bionano Genomics, Inc. published its 2026 Q2 earnings call presentation. The slide deck was released in conjunction with the company's Q2 earnings call. This article was written by SA Transcripts, which publishes thousands of quarterly earnings call transcripts.

Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ...

Bionano Genomics Inc (BNGO) reported Q2 2026 revenue of $8.2 million, a 21% year-over-year increase, exceeding guidance, driven by record flow cell sales. Despite strong demand and increased gross margins, the company faces supply constraints for flow cells and a decline in software revenue. …

Bionano Genomics, Inc. Q2 2026 Earnings Call Summary

Bionano Genomics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Bionano Genomics earnings beat by $0.13, revenue topped estimates

Bionano outlines $31M-$33M 2026 revenue forecast amid flow cell supply constraints

Earnings Call Insights: Bionano Genomics (BNGO) Q2 2026 MANAGEMENT VIEW * "Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers," said (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer Albert Luderer), adding …

Is Bionano Genomics Inc (BNGO) Undervalued After Q2 Earnings? EPS: -$7.4M, Revenue: $8.2M, GF Score: 64/100

Earnings call transcript: Bionano Genomics tops Q2 revenue view, shares edge up

Bionano Genomics (NASDAQ: BNGO) grows revenue amid going concern warning

Bionano Genomics presenta sus previsiones de ingresos para el tercer trimestre y el ejercicio 2026

Bionano Genomics, Inc. Q2 2026: Revenue $8.17M, EPS $(0.64) — 10-Q Summary

Bionano Genomics, Inc. reported its Q2 2026 financial results, showing a 21% increase in revenue to $8.17M, up from $6.73M in Q2 2025. Despite this growth, the company recorded a net loss of $7.42M, though the diluted EPS improved significantly from $(1.99) to $(0.64) …

Bionano Reports Second Quarter 2026 Results and Provides a Business Update

Bionano has reported its second-quarter 2026 financial results, which include updates on its operational performance and strategic initiatives. The company also provided a comprehensive business update detailing its progress and future outlook.

Bionano Genomics (BNGO) Earnings Date and Reports 2026

Bionano Genomics Inc (BNGO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bionano Genomics | 8-K: Current report

This article is a current report (8-K filing) from Bionano Genomics. It provides links to two separate documents for more details. The content explicitly states that it is for informational and educational purposes only and does not constitute investment advice.

Noticias de acciones de Bionano Genomics Inc (BNGO)

BioNano Genomics Inc (0A4K) Q1 2026 Earnings Report - Results, Call & Slides

BioNano Genomics Inc. (0A4K) reported its Q1 2026 earnings, beating analyst expectations with an EPS of -$0.76 against a consensus of -$0.88 and revenue of $6.69M, surpassing the expected $6.57M. The company highlighted positive operational developments including record flow cell sales, strong consumables growth, …

Bionano Genomics, Inc. expected to post a loss of 68 cents a share - Earnings Preview

Bionano Genomics, Inc. is projected to report a loss of 68 cents per share, according to this earnings preview. The article, provided by Refinitiv and featured on TradingView News, offers a brief overview of the upcoming financial expectation for BNGO. Readers can access the …

Bionano Genomics Inc (BNGO) Stock News Today

This article provides current stock information for Bionano Genomics Inc (BNGO), showing a recent increase of 5.45%. It indicates that more news regarding BNGO's stock, earnings, and analyst ratings will be available soon. The page serves as a hub for financial data and updates …

BNGO Q2'26 Earnings: EPS estimate is (0.67) USD

Bionano Genomics, Inc. (BNGO) is scheduled to release its Q2'26 financial results on August 10, after market close. The company is expected to report an estimated revenue of $7.55 million and an estimated earnings per share (EPS) of ($0.67) for the quarter. This article …

Bionano Genomics (BNGO) grants 5,000 options to officer

Bionano Genomics (BNGO) reported that its Principal Accounting Officer, Mark Adamchak, received a grant of 5,000 stock options. These options have an exercise price of $1.12 per share, vest 50% on the first and second anniversaries of the vesting commencement date, and expire on …

Bionano Genomics (NASDAQ: BNGO) awards 15,000 options to its general counsel

Bionano Genomics (NASDAQ: BNGO) has granted 15,000 stock options to its General Counsel, Jonathan V. Dixon, on August 3, 2026. The options have an exercise price of $1.12 per share and will expire on August 2, 2036. These options vest 50% on each of …

Bionano Genomics, Inc. (BNGO) CSO lists 54,000-share stock option position

Bionano Genomics, Inc. (BNGO) Chief Scientific Officer Hastie Alex Reid has reported a stock option to buy 54,000 shares of common stock at an exercise price of $1.12 per share, expiring on August 2, 2036. The vesting schedule includes 25% of the shares becoming …

Earnings Preview: BNGO to Report Financial Results Post-market on August 10

Bionano Genomics (BNGO) is scheduled to report its financial results on August 10 after the market closes. Analysts are anticipating a loss of $0.06 per share on revenue of $10.14 million for the quarter. This release will provide investors with an update on the …

Bionano Genomics, Inc. Revenue Breakdown – NASDAQ:BNGO

Bionano Genomics, Inc. reported a total revenue of $28.51 million USD last year. The largest contributing segment was Consumables, generating $13.97 million USD, an increase from $12.77 million USD in the prior year. Geographically, the EMEA region was the primary revenue driver, contributing $14.11 …

Diluted shares outstanding of Bionano Genomics, Inc. – GETTEX:2Y3

This article provides financial information for Bionano Genomics, Inc. (GETTEX:2Y3), specifically focusing on its diluted shares outstanding. The content is presented within the TradingView platform, offering various financial data points and tools for analysis.

Net income before discontinued operations of Bionano Genomics, Inc. – GETTEX:2Y3

This page provides financial data, specifically net income before discontinued operations, for Bionano Genomics, Inc. (2Y3) listed on Gettex. The content is primarily a data placeholder within TradingView's platform, indicating no trades have occurred for this particular metric yet.

Bionano Genomics Inc (BNGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bionano Genomics Inc (BNGO), detailing its price momentum score of 3.18 and identifying current support at $1.00 and resistance at $1.16. It presents a summary of various technical indicators, such as MACD and RSI, which largely suggest …

Bionano Genomics (BNGO) CSO reports holding 63 shares

Bionano Genomics' Chief Scientific Officer, Alex Reid Hastie, has filed an initial statement of beneficial ownership (Form 3) reporting direct ownership of 63 shares of the company's common stock. This filing indicates no insider purchases or sales in this specific report. It establishes his …

Bionano Genomics Inc (BNGO) Financial Health: Profitability & Balance Sheet Analysis

Bionano Genomics Inc (BNGO) has a weak financial score of 5.95, ranking 180 out of 199 in its industry due to low operating efficiency. Despite this, its latest quarterly revenue increased by 3.56% year-over-year, and net profit saw a significant 167.67% year-over-year increase. The …

Bionano Genomics Inc (BNGO) Institutional Confidence

Bionano Genomics Inc (BNGO) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 354.71% quarter-over-quarter to 10.52%. James Simons is the largest institutional shareholder, holding 0.44% of …

Bionano Genomics Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast

Bionano Genomics, Inc. has announced it will host a conference call and live webcast on August 10, 2026, at 4:30 p.m. Eastern Time. The purpose of the call is to discuss the company's financial results for the second quarter of 2026 and provide updates …

BNGO|Bionano Genomics Inc|Price:1.075|Chg%:-0.005

This article provides a comprehensive stock analysis of Bionano Genomics Inc (BNGO) by TradingKey, detailing its financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment. It highlights the company's significant growth potential, relatively stable fundamentals, and a "Buy" rating from multiple …

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

Bionano Genomics, Inc. (Nasdaq: BNGO) has announced that it will hold a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. ET. The event will cover the company's financial results for the second quarter of 2026 and highlight recent corporate …